X-Linked SCID: Correcting His Own Cells or Using His Father’s
A ten-day-old boy with X-linked SCID, caught by newborn screening before any infection took hold. The disagreement isn’t about whether to treat — it’s about which corrected immune system reaches him first: his own gene-repaired cells, or his father’s marrow.
Malik R. is ten days old, the second son of a Milwaukee sheet-metal worker and his wife, born two weeks after his parents finished repainting the nursery his older sister had used four years earlier. He has never been sick a day of his short life, which is exactly what the newborn screen was designed to catch before anyone could tell by looking at him: a T-cell receptor excision circle count of zero on repeat testing, followed within a week by genetic sequencing showing a novel IL2RG variant — X-linked severe combined immunodeficiency, the same diagnosis that a generation ago went uncaught until a first infection, and was often fatal by the time it was.
He is TREC-negative and profoundly T-lymphopenic, yet by every bedside measure he is well — feeding, growing, no fever, no thrush — only because he has not yet met a pathogen his immune system cannot answer. That window is the entire argument. Universal TREC screening only reached his state's newborn panel eight years ago; his own mother, tested retroactively as an obligate carrier, never had a diagnosed brother or cousin, because a generation earlier this same mutation would simply have looked like an unexplained infant death. His parents were told at diagnosis that two real, non-experimental paths now exist: correcting his own harvested stem cells with a normal copy of IL2RG and returning them after low-dose conditioning, the approach that carried seven of eight infants into durable trilineage immunity with no second immune system to reject or be rejected by; or a haploidentical transplant using his father, who typed as an immediate half-match, using graft-engineering techniques with a far longer track record.
Neither path is unproven. What is genuinely unsettled is which one, at this hospital and for this family, actually reaches him before his current advantage — a naive, unchallenged immune system — runs out. One side of that question is already settled, and not by logistics: the lentiviral protocol administers its busulfan only between two months and one year of age, and its eight published infants were a median of three and a half months old when they were treated. At ten days Malik is roughly seven weeks short of the earliest date he could be conditioned at all, before a single day of harvest or vector manufacturing is counted against him. His father, who has already used most of his paid leave on the newborn screen follow-up appointments, would need to clear a full donor workup on top of whatever recovery a bone-marrow harvest requires; the gene-therapy protocol, meanwhile, exists at only two centers nationally, neither of them the one where Malik was born.
At diagnosis, choosing which repair to build
Enroll him in the lentiviral gene-therapy protocol. Mamcarz et al., 2019, New England Journal of Medicine, treated eight newly diagnosed SCID-X1 infants with low-dose, targeted busulfan and autologous CD34+ cells corrected with a self-inactivating lentiviral vector carrying a normal IL2RG copy — seven of eight reconstituted full T-, B-, and NK-cell immunity, several eventually coming off intravenous immunoglobulin entirely. I’ll concede the age point before anyone raises it: that cohort’s median age at treatment was three and a half months, and the protocol will not condition Malik until he is two months old. There is no second immune system involved in that procedure, which means no graft-versus-host disease ever — not a reduced risk, an absent one.
I’m not dismissing his father’s match — a ready haploidentical donor is a real asset most families in his position don’t have. I’m saying the corrected-cell approach removes an entire category of long-term risk that even a beautifully matched allograft can’t.
You’re right that removing graft-versus-host risk entirely is a real advantage — I’m not contesting the biology. What the trial doesn’t settle is timing at this hospital. That protocol enrolls at two centers, and its conditioning window doesn’t open until two months — so we are seven weeks out before we add harvest, vector manufacturing, and release testing on top of it. His father is HLA-typed and available today.
Seven of eight reconstituting is an excellent result — in infants old enough to be conditioned the week they enrolled. Malik isn’t one of them yet, and the weeks he spends waiting to become one are weeks his maternal antibody is draining away.
Neither the busulfan pharmacokinetics nor the conditioning regimen is the actual bottleneck — the calendar is, and one side of it is fixed by protocol rather than by queue. The gene-therapy arm cannot condition him before two months of age however fast anyone moves; the haploidentical arm has no such floor. So the question isn’t which program is faster in the abstract. It is whether this transplant program can get his father’s cells into him inside the seven weeks the other pathway has to wait out regardless. Call both today and get real dates, but measure them against that floor, not against each other.
Both programs were called the same afternoon. The gene-therapy site quoted roughly five weeks from enrollment to infusion given its current manufacturing queue, running concurrently with the wait to two months rather than after it, so the earliest realistic infusion still fell just past his ninth week; the transplant program could proceed with the father’s haploidentical harvest within ten days, since he was already typed and cleared. Given that gap, the family chose to proceed with transplant while keeping gene therapy on record as a fallback if engraftment fails.
Not agreed, and carried forward rather than smoothed over: the immunologist still holds that a closer timeline gap should have favored gene therapy on the biology alone, while the transplant physician holds that even an equal timeline would have leaned him toward transplant given decades of long-term follow-up data gene therapy doesn’t yet have.
The gene-therapy protocol remains open to him; his own cells were never conditioned away and nothing about a failed allograft forecloses autologous correction later.
Routine post-transplant immune reconstitution monitoring proceeds on the standard schedule, with immunoglobulin replacement weaned only once his own antibody production is confirmed.